E1	Procedure:T1
E2	Negation:T2 Negates:E1
E3	Or:T3 Arg:E2 Arg2:E4
E4	Drug:T4 Name:T53 Temporality:E33
E5	Or:T5 Arg:E4 Arg2:E6
E6	Drug:T6 Name:T33
E7	Or:T7 Arg:E4 Arg2:E8
E8	Drug:T8 Name:T34 Temporality:E33
E9	Drug:T9 Name:T35
E10	Or:T10 Arg:E8 Arg2:E11
E11	Drug:T11 Name:T36 Temporality:E33
E12	Drug:T12 Name:T37
E13	Condition:T13 Name:T38
E16	And:T16 Arg:E13
E17	Or:T17 Arg:E16 Arg2:E35
E18	Modifier:T18 Modifies:T44
E19	Condition:T19 Name:T44
E20	Eq-Comparison:T20 Temporal-Period:T45
E21	Procedure:T21 Name:T46 Temporality:E20
E22	Drug:T22 Name:T47
E23	Or:T23 Arg:E22 Arg2:E24
E24	Drug:T24 Name:T48
E25	Eq-Comparison:T25 Operator:T50 Value:T51 Temporal-Unit:T52
E26	Temporal-Connection:T26 Arg:E25 Arg2:E28
E27	Procedure:T27 Temporality:E28
E28	Eq-Comparison:T28 Temporal-Recency:T49
E29	Temporal-Connection:T29 Arg:E30
E30	Study:T30
E31	Negation:T31 Negates:E42
E32	Procedure:T32 Name:T59
E33	Eq-Comparison:T54 Temporal-Period:T55
E34	And:T56 Arg:E12 Arg2:E13
E35	Negation:T57 Negates:E19
E14	Modifier:T14 Modifies:T38
E15	Modifier:T15 Modifies:T38
E36	Modifier:T39 Modifies:T38
E37	Modifier:T40 Modifies:T38
E38	Modifier:T41 Modifies:T38
E39	Modifier:T42 Modifies:T38
E40	Modifier:T43 Modifies:T38
E41	Or:T58 Arg:E39 Arg2:E40
E42	Study:T60 Study-Of:E32
T1	Procedure 36 34	Treatment
T2	Negation 44 40	na√Øve
T3	Or 47 43	or
T4	Drug 56 52	pegIFN
T5	Or 61 56	or
T6	Drug 65 60	IFN
T7	Or 79 69	and/or
T8	Drug 89 79	Ribavirin
T9	Drug 95 84	RBV
T10	Or 106 92	and/or
T11	Drug 117 103	sofosbuvir
T12	Drug 123 108	PRS
T13	Condition 156 140	CHC
T16	And 206 177	with
T17	Or 209 180	or
T18	Modifier 229 200	compensated
T19	Condition 239 210	cirrhosis
T20	Eq-Comparison 251 221	receiving
T21	Procedure 271 241	combination therapy
T22	Drug 293 263	oral GLE
T23	Or 295 264	/
T24	Drug 299 267	PIB
T25	Eq-Comparison 444 408	up to 4 weeks
T26	Temporal-Connection 450 414	after
T27	Procedure 460 424	treatment
T28	Eq-Comparison 471 435	initiation
T29	Temporal-Connection 547 509	prior
T30	Study 575 537	study
T31	Negation 600 560	not
T32	Procedure 688 648	therapeutic
T33	Drug-Name 65 60	IFN
T34	Drug-Name 89 79	Ribavirin
T35	Drug-Name 95 84	RBV
T36	Drug-Name 117 103	sofosbuvir
T37	Drug-Name 123 108	PRS
T38	Condition-Name 156 140	CHC
T44	Condition-Name 239 210	cirrhosis
T45	Eq-Temporal-Period 251 221	receiving
T46	Procedure-Name 271 241	combination therapy
T47	Drug-Name 293 263	oral GLE
T48	Drug-Name 299 267	PIB
T50	Eq-Operator 435 400	up to
T51	Eq-Value 438 402	4
T52	Eq-Temporal-Unit 444 408	weeks
T53	Drug-Name 56 52	pegIFN
T54	Eq-Comparison 137 121	experienced
T55	Eq-Temporal-Period 137 121	experienced
T56	And 142 126	with
T57	Negation 217 188	without
T14	Modifier 168 151	genotypes
T15	Modifier 171 153	1
T39	Modifier 176 156	2
T40	Modifier 181 159	3
T41	Modifier 186 162	4
T42	Modifier 191 165	5
T43	Modifier 199 171	6
T58	Or 196 169	or
T49	Eq-Temporal-Recency 471 435	initiation
T59	Procedure-Name 688 648	therapeutic
T60	Study 694 654	trial
A1	Temporal-Connection-Type-Value E26 after
A2	Temporal-Connection-Type-Value E29 before
A3	Eq-Temporal-Period-Value T45 present
A5	Eq-Operator-Value T50 LTEQ
A6	Eq-Temporal-Unit-Value T52 week
A7	Eq-Temporal-Period-Value T55 past
A4	Eq-Temporal-Recency-Value T49 first-time
R1	Abbrev-Of Arg1:E9 Arg2:E8
R2	Abbrev-Of Arg1:E12 Arg2:E11
R3	Using Arg1:E21 Arg2:E22
R4	Using Arg1:E21 Arg2:E24